Rezdiffra® treatment significantly improved liver stiffness, fibrosis biomarkers, and markers of clinically significant portal hypertension risk in patients with compensated MASH cirrhosis Rezdiffra ...

Two oral presentations to highlight biomarker, imaging and quality-of-life data from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial of RezdiffraPoster of ...

Basel, October 19, 2025 – Novartis today presents new Pluvicto™ (lutetium (177 Lu) vipivotide tetraxetan) data from the Phase III PSMAddition trial in a Presidential Symposium at the European Society ...

Jules performs better than Gemini CLI despite using the same model, and more like Claude Code and OpenAI Codex.

In the Phase III results presented and published today, olezarsen demonstrated rapid, substantial and significant reductions in triglycerides by up to 72% on top of standard of care and reduced the ...

Glass House Brands Inc. ( OTC:GLASF) Q3 2025 Earnings Call November 12, 2025 5:00 PM EST Good afternoon, ladies and gentlemen. Welcome to the Glass House Brands Third Quarter 2025 Earnings Call.

When the Originality Benchmark Dataset was revisited following an independent audit, something significant was discovered. Facticity.AI, the automated fact-checking engine that powers ArAIstotle, ...

LOUISVILLE, Ky. (WDRB) -- Real guns, fake guns and knives have all been confiscated at Jefferson County Public Schools this year, raising concerns among parents about student safety. District records ...

Heart failure with preserved ejection fraction, or HFpEF, is now the most common form of heart failure. Many people who ...

Acurx Pharmaceuticals, Inc. ("Acurx" or the "Company"), is a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections. It announced today ...

HIGHLIGHTS: Koné project comprises 7 mineralised trends hosting 52 identified targets with mineralization confirmed at all 23 ...